NU5.F · Solon Eiendom ASA

-

Please sign in to comment on NU5.F

1 Comment

Admin

4 years, 1 month ago

Solon Eiendom ASA is currently in a long term downtrend where the price is trading 0.2% below its 200 day moving average.

From a valuation standpoint, the stock is 62.9% cheaper than other stocks from the Real Estate sector with a price to sales ratio of 2.4.

Solon Eiendom ASA's total revenue sank by 10.3% to $292M since the same quarter in the previous year.

Its net income has dropped by 183.8% to $-42M since the same quarter in the previous year.

Finally, its free cash flow grew by 148.5% to $420M since the same quarter in the previous year.

Based on the above factors, Solon Eiendom ASA gets an overall score of 2/5.

ISIN	None
Exchange	F
CurrencyCode	EUR
Sector	Real Estate
Industry	Real Estate - Development

PE Ratio	7.85
Target Price	44
Dividend Yield	0.0%
Market Cap	355M
Beta	0.47

ABOUT

Solon Eiendom ASA

Solon Eiendom ASA acquires, develops, and sells residential real estate properties in Norway. The company was formerly known as Bionor Pharma ASA and changed its name to Solon Eiendom ASA. The company was founded in 2006 and is based in Oslo, Norway. Solon Eiendom ASA is a subsidiary of Samhällsbyggnadsbolaget i Norden AB (publ). As on January 20, 2022, Solon Eiendom ASA was taken private.

NU5.F · Solon Eiendom ASA

-

Solon Eiendom ASA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Solon Eiendom ASA using a moving average strategy